Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib and capecitabine in advanced metastatic colorectal cancer
NCT04866108Phase 2Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Dec 2021
- Primary completion
- Jun 2024
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of fruquintinib in colorectal cancer (metastatic) (mCRC), sponsored by Beijing Friendship Hospital. Status: unknown.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (metastatic) (mCRC)
Beyond the preview
Go deeper on NCT04866108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04866108.